Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2000

01-12-2000 | Paper Report

Enhanced activity of anti-Lewisyhumanised 3S193 when combined with Taxol

Author: Richard de Boer

Published in: Breast Cancer Research | Issue 1/2000

Login to get access

Excerpt

Monoclonal antibody (mAB) therapy is a potential new treatment option that selectively targets tumours and produces a therapeutic effect via the delivery of radiation or other toxins directly to tumour cells, or by producing an intrinsic immune inflammatory response. The Lewisy antigen (Ley) is a difucosylated oligosaccharide expressed on the surface of up to 60% of breast cancer cells, whilst rarely expressed on normal tissues. The humanised murine antibody, hu35193 has been shown to have high specificity for Ley. …
Literature
1.
Clarke K, Lee F-T, Brechbiel MW, Smyth FE, Old LJ, Scott AM: Therapeutic efficacy of anti-Lewisyhumanised 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with Taxol chemotherapy. Clin Cancer Res. 2000, 6: 3621-3628.PubMed
Metadata
Title
Enhanced activity of anti-Lewisyhumanised 3S193 when combined with Taxol
Author
Richard de Boer
Publication date
01-12-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2000-66718

Other articles of this Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Paper Report

Her-2/neu expression in primary breast cancer and its lymph node metastases

Paper Report

APCgene mutations in human breast cancers

Paper Report

Prognosis and treatment of small breast carcinomas

Paper Report

Is E-cadherin/catenin axis important in grade III ductal carcinomas?

Paper Report

Ang1 in breast cancer

Paper Report

Carbonic anhydrase expression in DCIS
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits